Insilico Medicine Ltd. has identified postsynaptic density-95 (PSD-95) protein inhibitors acting as neuroprotective agents reported to be useful for the treatment of epilepsy, anxiety disorders, neurodegeneration, neuropathic pain, stroke and cerebral infarction.